Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Surface Oncology, Inc.    SURF

SURFACE ONCOLOGY, INC.

(SURF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
Strengths
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 3.85 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at USD 9.47.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
SURFACE ONCOLOGY, INC.372.87%355
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.68%39 515
BEIGENE, LTD.82.54%27 421
GENMAB A/S50.39%23 222
BIONTECH SE158.91%20 893
HUALAN BIOLOGICAL ENGINEERI..98.35%15 640
ARGENX SE53.06%12 350
MYOKARDIA, INC.205.14%11 859
-
SAREPTA THERAPEUTICS, INC.6.37%10 776
NEUROCRINE BIOSCIENCES, INC..-10.86%8 936
ASCENDIS PHARMA A/S12.16%8 302
MIRATI THERAPEUTICS, INC.43.52%8 237
BIOCON LIMITED49.68%7 073
More Results
Financials (USD)
Sales 2020 38,6 M - -
Net income 2020 -25,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -12,1x
Yield 2020 -
Capitalization 355 M 355 M -
Capi. / Sales 2020 9,19x
Capi. / Sales 2021 94,6x
Nbr of Employees 49
Free-Float 98,3%
Upcoming event on SURFACE ONCOLOGY, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes